Celcuity to Release Third Quarter 2026 Financial Results
The Minneapolis-based biotechnology firm will announce its latest quarterly performance on November 5, 2026.
Updated on Oct. 29, 2026 in Public Companies
Live Poll
Do you trust emerging biotechnology companies to deliver consistent financial returns?
Celcuity Inc. is scheduled to release its third quarter 2026 financial results on November 5, 2026. Following the report, company management will conduct a conference call and live webcast to discuss the results.
Why it matters
The upcoming results will provide investors with an update on the company's financial standing and its ongoing efforts in developing targeted therapies for solid tumors.
The firm will host its conference call and webcast at 4:30 p.m. EST. Investors can join the domestic call by dialing 1-800-717-1738 or the international line at 1-646-307-1865.
The players
Celcuity Inc.
A biotechnology company headquartered in Minneapolis that focuses on developing targeted therapies for patients with solid tumors.
The details
Celcuity, based in Minneapolis, focuses on developing targeted therapies for solid tumor indications. The company currently manages several clinical trials, including the VIKTORIA-1 and VIKTORIA-2 studies for breast cancer, as well as the CELC-G-201 study for metastatic castration-resistant prostate cancer.
Timeline
November 5, 2026: Financial results will be released after the market closes.
November 5, 2026: Management will host a conference call and live webcast at 4:30 p.m. EST.
Market Landscape
The biotechnology industry relies heavily on trial outcomes and data releases to maintain market momentum for clinical-stage firms. Celcuity operates within this competitive sector, striving to advance its pipeline through rigorous adherence to the FDA's drug approval framework.
Shareholders and industry analysts will use the information disclosed during the November 5 webcast to assess the firm's fiscal health and project future growth. This event provides stakeholders with the necessary data to evaluate their investment positions in the company.
The takeaway
Investors should monitor the company's financial update for insights into clinical trial progress and operational spending. Reviewing the materials provided during the webcast can help stakeholders better understand the current trajectory of the company's therapeutic pipeline.
What happens next
Celcuity will release its third quarter 2026 financial results and host an investor call on November 5, 2026.
Further reading
For additional context on corporate developments in the area, visit the Minneapolis Public Companies section.
More information
To join the earnings discussion, visit the live webcast presentation link.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust emerging biotechnology companies to deliver consistent financial returns?
